Clinical Trial

Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer

Study acronym: PROSPETMR2021
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of multicentre phase 3 trial is evidence diagnostic value of 68Ga-PSMA-11 (in PET / CT and PET / MR techniques) in patients with high-risk and intermediate prostate cancer before radical treatment and in diagnosed patients biochemical recurrence after radical treatment
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-10-12; most recent amendment 2025-05-05.
Status change: Not Yet Recruiting → Recruiting 2023-09-21
Trial Details
NCT Number NCT05582876
Lead Sponsor Medical University of Bialystok
Collaborators: Medical Research Agency, Poland
Conditions Prostate Cancer
Enrollment 366 participants
Start Date 2023-01-10
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-08